134 related articles for article (PubMed ID: 34774650)
1. Refining the definition of biochemical failure in the era of stereotactic body radiation therapy for prostate cancer: The Phoenix definition and beyond.
Ma TM; Roy S; Wu X; Mantz C; Fuller D; Miszczyk L; Napieralska A; Namysł-Kaletka A; Bagshaw HP; Buyyounouski MK; Glicksman R; Loblaw DA; Katz A; Upadhyaya SK; Nickols N; Steinberg ML; Philipson R; Aghdam N; Suy S; Pepin A; Collins SP; Boutros P; Rettig MB; Calais J; Wang M; Zaorsky N; Kishan AU
Radiother Oncol; 2022 Jan; 166():1-7. PubMed ID: 34774650
[TBL] [Abstract][Full Text] [Related]
2. Prostate-specific antigen kinetics and biochemical control following stereotactic body radiation therapy, high dose rate brachytherapy, and low dose rate brachytherapy: A multi-institutional analysis of 3502 patients.
Levin-Epstein R; Cook RR; Wong JK; Stock RG; Jeffrey Demanes D; Collins SP; Aghdam N; Suy S; Mantz C; Katz AJ; Nickols NG; Miszczyk L; Napieralska A; Namysl-Kaletka A; Prionas ND; Bagshaw H; Buyyounouski MK; Cao M; Mahal BA; Shabsovich D; Dang A; Yuan Y; Rettig MB; Chang AJ; Jackson WC; Spratt DE; Lehrer EJ; Zaorsky NG; Kupelian PA; Steinberg ML; Horwitz EM; Jiang NY; Kishan AU
Radiother Oncol; 2020 Oct; 151():26-32. PubMed ID: 32663537
[TBL] [Abstract][Full Text] [Related]
3. Multi-Institutional Analysis of Prostate-Specific Antigen Kinetics After Stereotactic Body Radiation Therapy.
Jiang NY; Dang AT; Yuan Y; Chu FI; Shabsovich D; King CR; Collins SP; Aghdam N; Suy S; Mantz CA; Miszczyk L; Napieralska A; Namysl-Kaletka A; Bagshaw H; Prionas N; Buyyounouski MK; Jackson WC; Spratt DE; Nickols NG; Steinberg ML; Kupelian PA; Kishan AU
Int J Radiat Oncol Biol Phys; 2019 Nov; 105(3):628-636. PubMed ID: 31276777
[TBL] [Abstract][Full Text] [Related]
4. SBRT and HDR brachytherapy produce lower PSA nadirs and different PSA decay patterns than conventionally fractionated IMRT in patients with low- or intermediate-risk prostate cancer.
Kishan AU; Wang PC; Upadhyaya SK; Hauswald H; Demanes DJ; Nickols NG; Kamrava M; Sadeghi A; Kupelian PA; Steinberg ML; Prionas ND; Buyyounouski MK; King CR
Pract Radiat Oncol; 2016; 6(4):268-275. PubMed ID: 26850649
[TBL] [Abstract][Full Text] [Related]
5. Long-term results and PSA kinetics after robotic SBRT for prostate cancer: multicenter retrospective study in Korea (Korean radiation oncology group study 15-01).
Park Y; Park HJ; Jang WI; Jeong BK; Kim HJ; Chang AR
Radiat Oncol; 2018 Nov; 13(1):230. PubMed ID: 30470253
[TBL] [Abstract][Full Text] [Related]
6. Prostate-specific antigen kinetics following hypofractionated stereotactic body radiotherapy versus conventionally fractionated external beam radiotherapy for low- and intermediate-risk prostate cancer.
Lee SH; Kim HJ; Kim WC
Asia Pac J Clin Oncol; 2016 Dec; 12(4):388-395. PubMed ID: 27461444
[TBL] [Abstract][Full Text] [Related]
7. Early Prostate-Specific Antigen Kinetics for Low- and Intermediate-Risk Prostate Cancer Treated With Definitive Radiation Therapy.
Pirlamarla AK; Hansen CC; Deng M; Handorf E; Paly J; Wong JK; Hallman MA; Chen DYT; Geynisman DM; Kutikov A; Horwitz EM
Pract Radiat Oncol; 2022; 12(1):60-67. PubMed ID: 34303033
[TBL] [Abstract][Full Text] [Related]
8. Hypofractionated SBRT versus conventionally fractionated EBRT for prostate cancer: comparison of PSA slope and nadir.
Anwar M; Weinberg V; Chang AJ; Hsu IC; Roach M; Gottschalk A
Radiat Oncol; 2014 Feb; 9():42. PubMed ID: 24484652
[TBL] [Abstract][Full Text] [Related]
9. Does prostate-specific antigen nadir predict longer-term outcomes of prostate cancer after neoadjuvant and adjuvant androgen deprivation therapy in conjunction with brachytherapy?
Morris LM; Izard MA; Wan WY
Brachytherapy; 2015; 14(3):322-8. PubMed ID: 25487524
[TBL] [Abstract][Full Text] [Related]
10. Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience.
Chen LN; Suy S; Uhm S; Oermann EK; Ju AW; Chen V; Hanscom HN; Laing S; Kim JS; Lei S; Batipps GP; Kowalczyk K; Bandi G; Pahira J; McGeagh KG; Collins BT; Krishnan P; Dawson NA; Taylor KL; Dritschilo A; Lynch JH; Collins SP
Radiat Oncol; 2013 Mar; 8():58. PubMed ID: 23497695
[TBL] [Abstract][Full Text] [Related]
11. Prostate-specific antigen kinetics following hypofractionated stereotactic body radiotherapy boost and whole pelvic radiotherapy for intermediate- and high-risk prostate cancer.
Kim HJ; Phak JH; Kim WC
Asia Pac J Clin Oncol; 2017 Feb; 13(1):21-27. PubMed ID: 26969216
[TBL] [Abstract][Full Text] [Related]
12. Dose-response with stereotactic body radiotherapy for prostate cancer: A multi-institutional analysis of prostate-specific antigen kinetics and biochemical control.
Levin-Epstein RG; Jiang NY; Wang X; Upadhyaya SK; Collins SP; Suy S; Aghdam N; Mantz C; Katz AJ; Miszczyk L; Napieralska A; Namysl-Kaletka A; Prionas N; Bagshaw H; Buyyounouski MK; Cao M; Agazaryan N; Dang A; Yuan Y; Kupelian PA; Zaorsky NG; Spratt DE; Mohamad O; Feng FY; Mahal BA; Boutros PC; Kishan AU; Juarez J; Shabsovich D; Jiang T; Kahlon S; Patel A; Patel J; Nickols NG; Steinberg ML; Fuller DB; Kishan AU
Radiother Oncol; 2021 Jan; 154():207-213. PubMed ID: 33035622
[TBL] [Abstract][Full Text] [Related]
13. PSA nadir of <0.5 ng/mL following brachytherapy for early-stage prostate adenocarcinoma is associated with freedom from prostate-specific antigen failure.
Ko EC; Stone NN; Stock RG
Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):600-7. PubMed ID: 21985944
[TBL] [Abstract][Full Text] [Related]
14. Analysis of prostate-specific antigen bounce after I(125) permanent seed implant for localised prostate cancer.
Mitchell DM; Swindell R; Elliott T; Wylie JP; Taylor CM; Logue JP
Radiother Oncol; 2008 Jul; 88(1):102-7. PubMed ID: 18453022
[TBL] [Abstract][Full Text] [Related]
15. Unification of a common biochemical failure definition for prostate cancer treated with brachytherapy or external beam radiotherapy with or without androgen deprivation.
Fitch DL; McGrath S; Martinez AA; Vicini FA; Kestin LL
Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1430-9. PubMed ID: 16765527
[TBL] [Abstract][Full Text] [Related]
16. Stereotactic body radiotherapy as monotherapy or post-external beam radiotherapy boost for prostate cancer: technique, early toxicity, and PSA response.
Jabbari S; Weinberg VK; Kaprealian T; Hsu IC; Ma L; Chuang C; Descovich M; Shiao S; Shinohara K; Roach M; Gottschalk AR
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):228-34. PubMed ID: 21183287
[TBL] [Abstract][Full Text] [Related]
17. Early and multiple PSA bounces can occur following high-dose prostate stereotactic body radiation therapy: Subset analysis of a phase 1/2 trial.
Kim DN; Straka C; Cho LC; Lotan Y; Yan J; Kavanagh B; Raben D; Cooley S; Brindle J; Xie XJ; Pistenmaa D; Timmerman R
Pract Radiat Oncol; 2017; 7(1):e43-e49. PubMed ID: 27637137
[TBL] [Abstract][Full Text] [Related]
18. PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: a multi-institutional analysis.
Ray ME; Thames HD; Levy LB; Horwitz EM; Kupelian PA; Martinez AA; Michalski JM; Pisansky TM; Shipley WU; Zelefsky MJ; Zietman AL; Kuban DA
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1140-50. PubMed ID: 16198506
[TBL] [Abstract][Full Text] [Related]
19. Clinical outcomes of whole pelvis radiotherapy and stereotactic body radiotherapy boost for intermediate- and high-risk prostate cancer.
Kim HJ; Phak JH; Kim WC
Asia Pac J Clin Oncol; 2017 Oct; 13(5):e342-e347. PubMed ID: 26846353
[TBL] [Abstract][Full Text] [Related]
20. Prostate specific antigen kinetics following robotic stereotactic body radiotherapy for localized prostate cancer.
Kole TP; Chen LN; Obayomi-Davies O; Kim JS; Lei S; Suy S; Dritschilo A; Collins SP
Acta Oncol; 2015 Jun; 54(6):832-8. PubMed ID: 25467965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
